Concord Biotech Limited (CONCORDBIO) - Total Assets
Based on the latest financial reports, Concord Biotech Limited (CONCORDBIO) holds total assets worth Rs20.23 Billion INR (≈ $218.80 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check cash flow reinvestment rate of Concord Biotech Limited to assess the company's total reinvestment commitment from operating cash flow.
Concord Biotech Limited - Total Assets Trend (2020–2025)
This chart illustrates how Concord Biotech Limited's total assets have evolved over time, based on quarterly financial data. Check Concord Biotech Limited cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Concord Biotech Limited - Asset Composition Analysis
Current Asset Composition (March 2025)
Concord Biotech Limited's total assets of Rs20.23 Billion consist of 55.8% current assets and 44.2% non-current assets.
| Asset Category | Amount (INR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 0.1% |
| Accounts Receivable | Rs5.22 Billion | 25.6% |
| Inventory | Rs2.40 Billion | 11.8% |
| Property, Plant & Equipment | Rs0.00 | 0.0% |
| Intangible Assets | Rs11.22 Million | 0.1% |
| Goodwill | Rs0.00 | 0.0% |
Asset Composition Trend (2020–2025)
This chart illustrates how Concord Biotech Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Concord Biotech Limited (CONCORDBIO) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Concord Biotech Limited's current assets represent 55.8% of total assets in 2025, an increase from 4.9% in 2020.
- Cash Position: Cash and equivalents constituted 0.1% of total assets in 2025, down from 4.9% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2020.
- Asset Diversification: The largest asset category is accounts receivable at 25.6% of total assets.
Concord Biotech Limited Competitors by Total Assets
Key competitors of Concord Biotech Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE
|
USA | $763.95 Million |
|
3SBio Inc
F:83B
|
Germany | €36.25 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497
|
China | CN¥4.48 Billion |
|
Novavax Inc
NASDAQ:NVAX
|
USA | $1.04 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Concord Biotech Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.97 | 6.60 | 3.79 |
| Quick Ratio | 5.18 | 4.83 | 2.69 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Rs9.25 Billion | Rs7.93 Billion | Rs5.36 Billion |
Concord Biotech Limited - Advanced Valuation Insights
This section examines the relationship between Concord Biotech Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 7.60 |
| Latest Market Cap to Assets Ratio | 0.07 |
| Asset Growth Rate (YoY) | 19.6% |
| Total Assets | Rs20.34 Billion |
| Market Capitalization | $1.52 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Concord Biotech Limited's assets below their book value (0.07x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Concord Biotech Limited's assets grew by 19.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Concord Biotech Limited (2020–2025)
The table below shows the annual total assets of Concord Biotech Limited from 2020 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | Rs20.34 Billion ≈ $220.00 Million |
+19.61% |
| 2024-03-31 | Rs17.01 Billion ≈ $183.93 Million |
+12.33% |
| 2023-03-31 | Rs15.14 Billion ≈ $163.73 Million |
+15.33% |
| 2022-03-31 | Rs13.13 Billion ≈ $141.97 Million |
+11.01% |
| 2021-03-31 | Rs11.83 Billion ≈ $127.89 Million |
+25.73% |
| 2020-03-31 | Rs9.41 Billion ≈ $101.71 Million |
-- |
About Concord Biotech Limited
Concord Biotech Limited, a biopharma company, engages in the research and development, manufacture, market, and sale of pharmaceutical products in India and internationally. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenola… Read more